AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Delisting riskEarnings are out

IMMP · NASDAQ · Biotechnology

Immutep (ADR) (IMMP)

Develops LAG-3 immunotherapies for cancer and autoimmune disease.

$0.3701

Pre-market−0.01 (−3.34%)

At close$0.3829(+3.15%)

Watchlist

In millions of USD, except per-share figures · converted from AUD at the latest rate

In millions	Q2 FY21Dec 2020	Q4 FY21Jun 2021	Q2 FY22Dec 2021	Q4 FY22Jun 2022	Q2 FY23Dec 2022	Q4 FY23Jun 2023	Q2 FY24Dec 2023	Q4 FY24Jun 2024	Q2 FY25Dec 2024	Q4 FY25Jun 2025	Q2 FY26Dec 2025	Q4 FY26Jun 2026
Revenue	2	1	1	0	1	1	2	1	2	1	4	8
Cost of revenue	1	1	1	1	1	1	1	15	18	26	34	1
Gross profit	1	0	1	−1	1	1	1	−14	−16	−25	−29	7
	8	7	13	13	16	15	18	18	21	29	4	35
Research & development	7	2	11	8	14	7	15	15	18	26	0	0
	8	7	13	13	16	15	3	3	3	3	4	35
Selling & marketing	2	5	10	11	13	12	0	0	0	0	0	0
General & administrative	2	2	3	2	3	3	3	3	3	3	4	0
Operating income	−9	−8	−14	−14	−17	−16	−31	−32	−37	−54	−33	−28
	0	1	2	8	2	2	16	17	21	26	1	3
Interest income	0	0	0	0	0	0	1	1	2	2	1	1
Interest expense	0	0	0	0	0	0	0	0	0	0	0	0
Other non-operating income	−7	−2	−1	−8	−1	−1	−15	−15	−18	−26	0	0
Income before tax	−14	−7	−12	−11	−15	−14	−15	−15	−16	−28	−32	−25
Income tax expense	0	0	0	0	0	0	0	0	0	0	0	0
Net income from continuing operations	−14	−7	−12	−11	−15	−14	−15	−15	−16	−28	−32	−25
Net income	−14	−7	−12	−11	−15	−14	−15	−15	−16	−28	−32	−25
EPS, basic	−$0.27	−$0.09	−$0.14	−$0.13	−$0.17	−$0.15	−$0.13	−$0.13	−$0.11	−$0.19	−$0.22	−$0.17
EPS, diluted	−$0.27	−$0.09	−$0.14	−$0.13	−$0.17	−$0.15	−$0.13	−$0.13	−$0.11	−$0.19	−$0.22	−$0.17
Weighted average shares, basic	53	77	86	88	90	92	120	121	145	146	147	147
Weighted average shares, diluted	53	77	86	88	90	92	120	122	145	146	147	147
EBITDA	−7	−6	−11	−13	−15	−14	−16	−16	−19	−26	−32	−28
Depreciation & amortization	1	1	1	1	1	1	1	1	0	2	1	1
EBIT	−7	−7	−12	−12	−15	−14	−17	−17	−19	−28	−33	−28